Delpharm to Expand and Upgrade Boucherville Site

Delpharm is modernizing its Boucherville facility with a $60 million contribution from the Québec government. This contribution adds to the previously confirmed $60 million investment from the federal government, announced last March, along with $100 million in private capital, bringing the total to $220 million. By 2031, this investment aims to transform Delpharm’s Boucherville site into a world-class pharmaceutical facility.

The project will expand the plant and install a new state-of-the-art sterile filling line. It will also replace 95% of the existing equipment and significantly increase production capacity to meet the growing demand for injectable drugs. 

“We would like to acknowledge the commitment of the Ministry of Economy, Innovation and Energy, a key partner in strengthening Québec’s pharmaceutical autonomy. We also wish to recognize our long-standing partner Sandoz, with whom we have renewed a 10-year contract to produce generic hospital medicines. This agreement guarantees patients in Québec and across Canada a local, stable, and reliable supply,” said Mathieu Grondin, Site Director at Delpharm Boucherville.

Delpharm Boucherville plays a strategic role in the supply of essential medicines. According to a study commissioned by its partner Sandoz, the site produces 20 of the 100 most important medicines in the Canadian healthcare system. These sterile injectable drugs are used daily in operating rooms and intensive care units across the country. 

Delpharm will repay over time $105 of the $120 million in government support, in addition to dividends to be paid by the company to the Québec government.